Pictilisib (GDC-0941)
别名: RG7321
目录号:S1065 Purity: 99.97%
Pictilisib (GDC-0941, RG7321) 是一种有效的PI3Kα/δ抑制剂,在无细胞试验中IC50为 3 nM,对p110β (11倍)和p110γ (25倍)具有适度的选择性。Pictilisib (GDC-0941) 可诱导自噬和凋亡。Phase 2。
CAS: 957054-30-7
客户使用Selleck的Pictilisib (GDC-0941)发表文献421篇
- Nature, 2024 10.1038/s41586-024-08031-6
- Nat Genet, 2024 10.1038/s41588-024-01948-8
- Nat Cell Biol, 2024 10.1038/s41556-024-01473-0
- Nature, 2023 620(7973):393-401
- Cell, 2023 186(25):5554-5568.e18
- Cancer Cell, 2021 S1535-6108(21)00383-4
- Cancer Cell, 2021 S1535-6108(21)00492-X
- Immunity, 2021 54(8):1807-1824.e14
- Cell, 2020 182(3):685-712.e19
- Nat Microbiol, 2020 10.1038/s41564-020-0782-1
- Nat Cell Biol, 2020 22(3):289-296
- Nat Med, 2019 25(5):838-849
- Nat Med, 2018 24(7):968-977
- Nat Med, 2018 24(7):954-960
- Cell, 2018 172(1-2):373-386
- Nat Biomed Eng, 2018 2(8):578-588
- Blood, 2018 10.1182/blood-2018-08-872465
- Nat Med, 2017 23(11):1342-1351
- Cell Discov, 2017 3:16054
- Immunity, 2017 47(6):1083-1099.e6
- Cell Host Microbe, 2017 21(5):611-618
- J Clin Oncol, 2016 34(8):794-802
- Cancer Discov, 2016 6(10):1134-1147
- Cancer Discov, 2016
- J Thorac Oncol, 2016 11(8):1345-1356
- Nat Med, 2015 21(9):1038-47
- Cancer Cell, 2015 27(4):561-73
- Cancer Discov, 2015 5(3):264-73
- Nature, 2014 508(7494):118-22
- Cancer Discov, 2014 4(1):94-109
- Cell, 2013 7;155(4):844-57.
- Blood, 2013 121(12):2274-84
- Cancer Discov, 2012 2(11):1036-47
- Cell Stem Cell, 2012 10(2):210-7
- Cancer Discov, 2011 1(7):608-25
- Nat Commun, 2024 15(1):7181
- Mol Cell, 2024 S1097-2765(24)00865-7
- EMBO Mol Med, 2024 10.1038/s44321-024-00120-3
- Cancer Lett, 2024 604:217219
- Cell Rep, 2024 43(9):114728
- Cell Rep, 2024 43(9):114710
- Front Immunol, 2024 15:1386719
- iScience, 2024 27(10):110939
- Am J Cancer Res, 2024 14(2):448-466
- Nat Commun, 2023 14(1):5242
- J Clin Invest, 2023 e168352
- J Med Virol, 2023 95(11):e29230
- Cancer Res, 2023 83(2):316-331
- JCI Insight, 2023 8(22)e164672
- JCI Insight, 2023 8(9)e163864
- Aging Cell, 2023 e13763.
- J Transl Med, 2023 21(1):923
- Cells, 2023 12(15)1964
- PLoS One, 2023 10.1371/journal.pone.0294065
- PLoS One, 2023 18(2):e0277326
- Yonsei Med J, 2023 64(2):139-147
- Res Sq, 2023 rs.3.rs-3154719
- Mol Cell Oncol, 2023 10(1):2238873
- Nat Commun, 2022 13(1):245
- Nat Chem Biol, 2022 10.1038/s41589-022-00996-7
- Nat Protoc, 2022 10.1038/s41596-022-00740-4
- Nat Chem Biol, 2022 10.1038/s41589-022-01150-z
- Clin Cancer Res, 2022 clincanres.4291.2021
- Clin Cancer Res, 2022 28-20:4444-4455
- Cancer Res, 2022 canres.1397.2021
- Cancer Res, 2022 canres.2609.2021
- Sci China Life Sci, 2022 10.1007/s11427-022-2185-9
- Cell Rep, 2022 39(6):110796
- Cell Rep, 2022 40(7):111194
- JCI Insight, 2022 e155899
- Biomed Pharmacother, 2022 156:113754
- Breast Cancer Res, 2022 24(1):23
- Front Immunol, 2022 13:970195
- Mol Cell Proteomics, 2022 S1535-9476(22)00048-2
- Cells, 2022 11(6)953
- NPJ Breast Cancer, 2022 8(1):125
- iScience, 2022 25(5):104211
- Mol Cancer Ther, 2022 21(6):1020-1029
- Cancer Sci, 2022 113(7):2323-2335
- Cancers (Basel), 2022 14(19)4727
- J Nat Prod, 2022 10.1021/acs.jnatprod.1c01154
- Oral Oncol, 2022 131:105939
- J Biol Chem, 2022 S0021-9258(22)00470-7
- Front Oncol, 2022 12:874325
- Molecules, 2022 27-165071
- Sci Rep, 2022 12(1):14821
- Molecules, 2022 27(12)3834
- Life Sci Alliance, 2022 5(11)e202201460
- Cancer Chemother Pharmacol, 2022 89(3):401-411
- Dev Biol, 2022 S0012-1606(22)00049-5
- J Radiat Res, 2022 rrac018
- Sci Adv, 2022 8(29):eabm8780
- Cancer Res Commun, 2022 2(12):1569-1578
- Nat Commun, 2021 12(1):5520
- Clin Cancer Res, 2021 27(9):2533-2548
- Cancer Res, 2021 canres.1547.2021
- Exp Hematol Oncol, 2021 10(1):19
- Cancer Lett, 2021 510:37-47
- Cell Death Dis, 2021 12(8):741
- Cell Death Dis, 2021 12(6):619
- Cell Rep, 2021 35(11):109238
- Cell Rep, 2021 34(7):108750
- Oncogene, 2021 10.1038/s41388-021-02029-4
- Phytomedicine, 2021 92:153713
- Cell Oncol (Dordr), 2021 10.1007/s13402-021-00628-7
- Int J Cancer, 2021 10.1002/ijc.33594
- Oncogenesis, 2021 10(1):8
- Cancer Cell Int, 2021 21(1):302
- Biomolecules, 2021 11(6)808
- J Cell Mol Med, 2021 10.1111/jcmm.16889
- Cancers (Basel), 2021 13(9)2139
- Front Oncol, 2021 11:618839
- Front Oncol, 2021 11:782065
- Front Oncol, 2021 11:648985
- Food Chem Toxicol, 2021 S0278-6915(21)00034-X
- PLoS Comput Biol, 2021 17(11):e1009515
- Front Med (Lausanne), 2021 8:713312
- Cardiovasc Toxicol, 2021 21(8):655-668
- Biochem Biophys Res Commun, 2021 552:23-29
- Biol Pharm Bull, 2021 10.1248/bpb.b21-00531
- J Burn Care Res, 2021 irz170
- ProQuest, 2021
- Cancer Rep (Hoboken), 2021 e1459
- Nat Commun, 2020 8;11(1):2291
- Nat Commun, 2020 11(1):1290
- Mol Cell, 2020 80(1):164-174.e4
- EMBO Mol Med, 2020 e11674
- Proc Natl Acad Sci U S A, 2020 117(39):24427-24433
- Proc Natl Acad Sci U S A, 2020 117(49):31189-31197
- EMBO Mol Med, 2020 12(8):e11987
- J Control Release, 2020 318:98-108
- Cell Syst, 2020 20;10(5):384-396.e9
- Cell Syst, 2020 10(3):240-253
- Cell Death Dis, 2020 11(9):765
- Cell Rep, 2020 31(12):107800
- Cell Rep, 2020 30(13):4584-4599
- Br J Cancer, 2020 22
- Br J Cancer, 2020 10.1038/s41416-020-0952-1
- JCI Insight, 2020 5(22)141832
- J Cell Biol, 2020 219(2)
- Blood Adv, 2020 4(18):4382-4392
- Sci Signal, 2020 13(637):eaba8627
- Cell Oncol (Dordr), 2020 8
- Mol Oncol, 2020 26
- Mol Cancer Ther, 2020 5;molcanther.1131.2019
- Am J Physiol Cell Physiol, 2020 10.1152/ajpcell.00290.2020
- Oncotarget, 2020 28;11(17):1493-1504
- Cancers (Basel), 2020 12(11)E3172
- Eur J Pharmacol, 2020 873:172981
- Front Oncol, 2020 1;10:393
- Sci Rep, 2020 4;10(1):7401
- Sci Rep, 2020 10(1):218
- Oncol Lett, 2020 20(1):533-540
- Sci Adv, 2020 6(34):eaba8968
- STAR Protoc, 2020 1(1)100016
- Nat Commun, 2019 10(1):2532
- Nat Commun, 2019 10(1):1473
- J Clin Invest, 2019 129(12):5584-5599
- Clin Cancer Res, 2019 10.1158/1078-0432
- Clin Cancer Res, 2019 25(9):2835-2847
- J Exp Clin Cancer Res, 2019 38(1):41
- J Exp Clin Cancer Res, 2019 38(1):236
- Cancer Res, 2019 79(11):2892-2908
- Cancer Res, 2019 79(6):1138-1150
- Haematologica, 2019 10.3324/haematol.2019.216218
- Haematologica, 2019 104(11):2225-2240
- Cancer Lett, 2019 466:23-34
- Cell Rep, 2019 27(1):294-306
- Cell Rep, 2019 27(2):631-647
- Cell Rep, 2019 28(9):2317-2330
- Acta Pharmacol Sin, 2019 40(5):677-688
- Oncogene, 2019 38(15):2690-2705
- J Transl Med, 2019 17(1):431
- Br J Pharmacol, 2019 176(3):436-450
- J Invest Dermatol, 2019 139(9):2004-2015
- Int J Cancer, 2019 145(3):817-829
- MBio, 2019 10(1)
- Cells, 2019 8(2)
- Cancer Biol Med, 2019 16(1):66-83
- Int J Mol Med, 2019 44(5):1789-1800
- J Cell Mol Med, 2019 23(2):920-933
- Mol Cancer Res, 2019 10.1158/1541-7786.MCR-18-1332
- Front Microbiol, 2019
- Mol Cancer Res, 2019 17(12):2395-2409
- Int J Oncol, 2019 54(2):431-442
- Pestic Biochem Physiol, 2019 154:67-77
- Sci Rep, 2019 9(1):1897
- Sci Rep, 2019
- Invest Ophthalmol Vis Sci, 2019 60(7):2764-2772
- Life Sci Alliance, 2019 2(6)
- Cancer Manag Res, 2019 11:839-855
- Contrast Media Mol Imaging, 2019 2019:1760184
- Nat Commun, 2018 9(1):4945
- Nat Commun, 2018 9(1):2434
- Mol Cell, 2018 71(6):1092-1104
- J Clin Invest, 2018 128(1):446-462
- Nat Chem Biol, 2018 14(8):768-777
- Clin Cancer Res, 2018 15;24(6):1436-1447
- Clin Cancer Res, 2018 24(23):6066-6077
- Cancer Res, 2018 78(15):4396-4410
- Cancer Res, 2018 78(13):3645-3658
- EBioMedicine, 2018 28:80-89
- Genes Dev, 2018 32(17-18):1201-1214
- Cancer Lett, 2018 439:56-65
- Cell Death Dis, 2018 9(8):809
- Cell Rep, 2018 22(4):860-868
- Oncogene, 2018 37(10):1369-1385
- JCI Insight, 2018 3(4)
- J Cell Biol, 2018 217(5):1701-1717
- J Invest Dermatol, 2018 138(11):2377-2387
- Am J Respir Cell Mol Biol, 2018 58(2):181-193
- Oncogenesis, 2018 7(9):71
- Bioinformatics, 2018 34(17):i997-i1004
- Bioinformatics, 2018 34(23):4079-4086
- J Am Heart Assoc, 2018 7(6)
- NPJ Genom Med, 2018 3:15
- Mol Cancer Res, 2018 16(3):543-553
- Int J Oncol, 2018 52(3):828-840
- Int J Oncol, 2018 53(5):1881-1896
- Cancers (Basel), 2018 10(12)
- Am J Physiol Lung Cell Mol Physiol, 2018 315(6):L965-L976
- Cell Signal, 2018 44:127-137
- Oncol Rep, 2018 40(2):715-725
- PLoS One, 2018 13(5):e0193849
- PLoS One, 2018 13(8):e0200725
- Proteomics, 2018 18(23):e1800244
- Invest New Drugs, 2018 36(5):763-772
- Prostate, 2018 78(13):1013-1023
- Anticancer Res, 2018 38(11):6195-6200
- Nat Commun, 2017 8(1):1090
- Nat Commun, 2017 8:13897
- Nat Commun, 2017 8(1):1278
- Nat Commun, 2017 8(1):2249
- Mol Cell, 2017 67(3):512-527
- Nucleic Acids Res, 2017 45(16):9654-9678
- Theranostics, 2017 7(4):974-986
- Clin Cancer Res, 2017 23(18):5561-5572
- Cancer Res, 2017 77(15):4135-4145
- Cancer Res, 2017 77(8):1892-1904
- Mol Syst Biol, 2017 13(1):905
- Oncogene, 2017 36(41):5681-5694
- Oncogene, 2017 36(36):5110-5121
- J Cell Biol, 2017 216(6):1567-1577
- Oncogenesis, 2017 6(11):398
- Mol Cancer Ther, 2017 16(2):285-299
- Mol Cancer Ther, 2017 10.1158/1535-7163.MCT-16-0415
- Mol Cancer Ther, 2017 16(6):1054-1067
- Mol Cancer Ther, 2017 16(10):2130-2143
- Oncotarget, 2017 8(5):7878-7890
- Oncotarget, 2017 8(4):6608-6622
- Oncotarget, 2017 8(2):3259-3273
- Oncotarget, 2017 8(11):17995-18009
- Oncotarget, 2017 8(3):4277-4288
- Oncotarget, 2017 8(3):5349-5360
- Oncotarget, 2017 8(8):12558-12575
- Oncotarget, 2017 8(26):42343-42358
- Oncotarget, 2017 8(38):63901-63910
- Oncotarget, 2017 8(32):52877-52888
- Oncotarget, 2017 8(47):83052-83062
- Oncotarget, 2017 9(10):8870-8886
- Mol Pharm, 2017 14(7):2368-2377
- Sci Rep, 2017 7(1):5519
- Sci Rep, 2017 7(1):3964
- J Immunol, 2017 198(2):657-668
- PLoS One, 2017 12(7):e0181243
- Am J Reprod Immunol, 2017 78(4)
- Mol Pharmacol, 2017 91(1):65-73
- Cancer Biol Ther, 2017 18(10):816-826
- Biol Reprod, 2017 97(5):671-687
- Biochem Biophys Res Commun, 2017 489(1):14-20
- SLAS Discov, 2017 22(5):507-515
- Curr Cancer Drug Targets, 2017 17(8):722-734
- Physiol Rep, 2017 5(18)
- Nat Commun, 2016 7:13650
- Nat Commun, 2016 7:13567
- Leukemia, 2016 30(9):1832-43
- Proc Natl Acad Sci U S A, 2016 113(6):1624-9
- Cell Rep, 2016 15(12):2692-704
- Oncogene, 2016 35(27):3587-97
- Elife, 2016 10.7554/eLife.18489
- Elife, 2016
- Mol Cancer Ther, 2016 15(6):1248-60
- Mol Cancer Ther, 2016
- Mol Cancer Ther, 2016 15(1):94-105
- Oncotarget, 2016 7(28):44448-44461
- Oncotarget, 2016 7(36):57525-57544
- Oncotarget, 2016
- Oncotarget, 2016 7(44):71211-71222
- Oncotarget, 2016 7(15):19575-88
- Oncotarget, 2016 7(8):9188-221
- Oncotarget, 2016 7(50):82424-82439
- Aging (Albany NY), 2016 8(12):3507-3519
- Mol Pharm, 2016 13(11):3724-3735
- Development, 2016 143(23):4368-4380
- Sci Rep, 2016
- PLoS Comput Biol, 2016 12(4):e1004827
- Pigment Cell Melanoma Res, 2016 29(3):317-28
- PLoS One, 2016 11(5):e0155230
- Nat Commun, 2015 6:7935
- Nat Commun, 2015 6:8501
- Nat Commun, 2015 6:7212
- J Exp Med, 2015 212(6):883-92
- Exp Mol Med, 2015 47:e143
- Proc Natl Acad Sci U S A, 2015 112(28):8638-43
- Mol Syst Biol, 2015 11(3):797
- Cell Death Dis, 2015 6:e1591
- Cell Death Dis, 2015 6:e1711
- Cell Commun Signal, 2015 13:26
- Elife, 2015 4
- Elife, 2015 4:e10510
- Sci Signal, 2015 8(401):ra111
- Sci Signal, 2015 8(396):ra96
- J Invest Dermatol, 2015 135(12):3115-3124
- Int J Cancer, 2015 10.1002/ijc.29579
- Crit Rev Oncol Hematol, 2015 96(3):507-17
- Oncotarget, 2015 6(11):9189-205
- Oncotarget, 2015 6(11):8722-35
- Oncotarget, 2015 6(41):43540-56
- Oncotarget, 2015 6(31):32089-103
- Oncotarget, 2015 6(22):18921-32
- Oncotarget, 2015 6(18):16488-506
- Oncotarget, 2015 6(18):15814-27
- Oncotarget, 2015 6(31):31792-804
- Oncotarget, 2015 6(7):5118-33
- Oncotarget, 2015 6(39):41976-87
- Oncotarget, 2015
- J Biol Chem, 2015 290(40):24367-80
- Neoplasia, 2015 17(8):625-33
- J Biol Chem, 2015
- Sci Rep, 2015 5:14739
- Pigment Cell Melanoma Res, 2015 28(5):572-89
- Cell Cycle, 2015 14(4):648-55
- PLoS One, 2015 10(4):e0122689
- PLoS One, 2015 10(9):e0133610
- PLoS One, 2015 10(11):e0143357
- PLoS One, 2015 10(7):e0131400
- Cancer Biol Ther, 2015 16(3):402-11
- Hum Mol Genet, 2015 24(4):926-38
- Proteomics, 2015 15(2-3):327-39
- Prostate, 2015 75(3):242-54
- Nat Struct Mol Biol, 2014 21(6):522-7
- Cancer Res, 2014 10.1158/0008-5472.CAN-14-1392
- Cancer Res, 2014 74(17):4597-4611
- Proc Natl Acad Sci U S A, 2014 111(47):16826-9
- Cell Death Dis, 2014 5:e1134
- Oncogene, 2014 33(26):3422-31
- Oncogene, 2014 33(8):966-76
- Oncogene, 2014 33(35):4418-23
- Oncogene, 2014 10.1038/onc.2014.328
- Oncogene, 2014 33(23):3043-53
- Breast Cancer Res, 2014 16(4):406
- Gastric Cancer, 2014 10.1007/s10120-014-0444-1
- Pain, 2014 155(6):1150-60
- Oncotarget, 2014 5(17):7328-41
- Oncotarget, 2014 5(15):6512-25
- Oncotarget, 2014 5(16):7081-92
- Oncotarget, 2014 5(13):5040-53
- Oncotarget, 2014 5(18):8737-49
- Oncotarget, 2014
- Am J Cancer Res, 2014 4(6):824-37
- Neoplasia, 2014 16(2):147-57
- J Biol Chem, 2014 289(33):22785-97
- J Immunol, 2014 193(6):3036-44
- Pigment Cell Melanoma Res, 2014 27(6):1154-8
- PLoS One, 2014 9(11):e112148
- PLoS One, 2014 9(9):e105919
- PLoS One, 2014 9(1):e84746
- Epigenetics, 2014 9(4):611-20
- Mol Med Rep, 2014 9(1):83-90
- Biochem Biophys Res Commun, 2014 10.1016/j.bbrc.2014.09.129
- Anticancer Drugs, 2014 25(2):183-8
- Harvard University, 2014
- Sci Transl Med, 2013 5(196):196ra98
- J Clin Invest, 2013 123(6):2551-63
- Cell Death Differ, 2013 21(3):491-502
- Clin Cancer Res, 2013 19(20):5749-57
- Clin Cancer Res, 2013 19(9):2584-91
- Clin Cancer Res, 2013 19(19):5413-22
- Clinical Cancer Research, 2013 19(9)
- Leukemia, 2013 27(11):2118-28
- Cancer Res, 2013 73(3):1190-200
- Haematologica, 2013 98(1):57-64
- Oncogene, 2013 33(9):1190-7
- Sci Signal, 2013 6(288):ra68
- Sci Signal, 2013
- Cancer Sci, 2013 104(8):1027-32
- Mol Cancer Ther, 2013 12(12):2950-61
- Oncotarget, 2013 4(8):1185-98
- J Biol Chem, 2013 288(21):14698-708
- PLoS Genet, 2013 9(2):e1003253
- Cell Cycle, 2013 12(12):1892-900
- J Cell Sci, 2013 126(Pt 5):1099-108
- Cancer Med, 2013 2(1):76-85
- PLoS One, 2013 8(6):e66306
- PLoS One, 2013 8(10):e77243
- Front Genet, 2013 4:34
- FEBS Lett, 2013 587(1):5-16
- Biochem Biophys Res Commun, 2013 435(4):557-61
- Mol Biosyst, 2013 9(2):234-45
- Leuk Res, 2013 38(1):109-15
- J Surg Res, 2013 184(2):898-906
- Clin Cancer Res, 2012 18(9):2502-14
- Clin Cancer Res, 2012 19(3):657-67
- Proc Natl Acad Sci USA, 2012 109(31):E2127-33
- Cell Death Dis, 2012 3:e400
- Eur J Cancer, 2012 48(6):936-43
- Cancer Sci, 2012 103(9):1665-71
- J Leukoc Biol, 2012 92(1):219-31
- Oncotarget, 2012 3(8):811-23
- Mol Cell Biol, 2012 32(22):4674-83
- Biochim Biophys Acta, 2012 1823(12):2210-6
- J Cell Sci, 2012 125(Pt 5):1259-73
- PLoS One, 2012 7(8):e44146
- PLoS One, 2012 7(9):e46518
- Clin Cancer Res, 2011 17(24):7595-604
- Clin Cancer Res, 2011 17(8):2260-9
- Cancer Res, 2011 71(7):2750-60
- P Natl Acad Sci USA, 2011 108(37):E699-708
- Sci Signal, 2011 4(192):ra62
- J Invest Dermatol, 2011 131(2):495-503
- Thyroid, 2010 20(7):689-95
化学信息&溶解度
分子量 | 513.64 |
分子式 | C23H27N7O3S2 |
CAS号 | 957054-30-7 |
Smiles | CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 194.68 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 44 mg/mL ( 85.66 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 194.68 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 194.68 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 194.68 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。